Neurovance

Neurovance, Inc. is a neuroscience-focused company dedicated to the development and commercialization of treatments for attention deficit hyperactivity disorder (ADHD) in both adults and children. The company has developed centanafadine, a triple reuptake inhibitor that modulates the activity of norepinephrine, dopamine, and serotonin in specific proportions. Neurovance, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.